Evidence map›Paper›PMID 42553595›Full record

ArticleBrain communications2026

Evaluating MAPT p.A152T as a risk factor for the 3R tauopathy Pick's disease.

Nicole Tamvaka, William Scotton, Meredith T Lilley, Maryam Shoai, Marios Gavrielatos, Michael G Heckman, Alexandra I Soto-Beasley, Shanu F Roemer, Matthew C Baker, Rosa Rademakers and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nicole TamvakaDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
William ScottonDementia Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London WC1E 6BT, UK.ORCID https://orcid.org/0000-0003-0607-3190
Meredith T LilleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Maryam ShoaiDepartment of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London WC1N 3BG, UK.
Marios GavrielatosDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Michael G HeckmanDivision of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL 32224, USA.
Alexandra I Soto-BeasleyDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Shanu F RoemerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Matthew C BakerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Rosa RademakersDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID https://orcid.org/0000-0001-7379-2545
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID https://orcid.org/0000-0001-7189-7917
John A HardyDepartment of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London WC1N 3BG, UK.
Casey N CookDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, University College London, Queen Square Institute of Neurology, London WC1E 6BT, UK.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID https://orcid.org/0000-0003-4813-756X
Pick’s disease international consortium
Pick’s disease international consortium

Funding

Project 1U19AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI RICHARD Justin PERRIN · 2016 to 2026
$226.7M
DIAN-TU: Tau Next Generation Prevention Trial - Administrative SupplementR01AG068319 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2020 to 2026
$81.4M
Vascular Structure and Function in Cognitive AgingP01AG003949 · NIA · YESHIVA UNIVERSITY · PI CAROL A. DERBY · 1985 to 2026
$73.9M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Medicinal Chemistry CoreU19NS110456 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI ROBERT H MACH · 2019 to 2026
$44.1M
The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)R01AG070883 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2021 to 2026
$42.1M
Project 4 (Genetic modifiers for APOE-associated Alzheimer's disease pathogenesis)U19AG069701 · NIA · MAYO CLINIC JACKSONVILLE · PI ALISON M GOATE, DAVID M. HOLTZMAN · 2021 to 2026
$42.0M
Project: Predicting PhenoconversionU19AG071754 · NIA · WASHINGTON UNIVERSITY · PI Bradley F Boeve, Yo-El S Ju · 2021 to 2026
$41.2M
Research Education ComponentP30AG010133 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI SAYKIN, ANDREW J · 1991 to 2020
$37.3M
NIA NIH HHS K08 AG052648NIA NIH HHS K08 AG065463NIA NIH HHS P01 AG003949NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P01 AG026276NIA NIH HHS P01 AG066597NIA NIH HHS P30 AG010124NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062677NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066462NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072977NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG052550NIA NIH HHS R01 AG053267NIA NIH HHS R01 AG054567NIA NIH HHS R01 AG056366NIA NIH HHS R01 AG058676NIA NIH HHS R01 AG062566NIA NIH HHS R01 AG063780NIA NIH HHS R01 AG068319NIA NIH HHS R01 AG070883NIA NIH HHS R01 AG074909NIA NIH HHS R01 AG077444NIA NIH HHS R01 AG087165NIA NIH HHS R01 AG089380NIA NIH HHS U19 AG024904NIA NIH HHS U19 AG032438NIA NIH HHS U19 AG069701NIA NIH HHS U19 AG071754NIDCD NIH HHS R01 DC008552NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS075075NINDS NIH HHS R01 NS075321NINDS NIH HHS R01 NS078086NINDS NIH HHS R01 NS092865NINDS NIH HHS R01 NS097799NINDS NIH HHS R01 NS109260NINDS NIH HHS R01 NS134586NINDS NIH HHS RF1 NS118584NINDS NIH HHS RF1 NS139970NINDS NIH HHS U01 NS100620NINDS NIH HHS U19 NS110456NINDS NIH HHS U24 NS072026NINDS NIH HHS U54 NS100693Wellcome Trust
6 · The paper itself

Abstract

Genetic studies have significantly advanced our understanding of tauopathies, yet the genetic aetiology of Pick's disease, a rare 3-Repeat tauopathy, remains unclear. The MAPT p.A152T variant has been identified as a risk factor for Alzheimer's disease and progressive supranuclear palsy, but its role in Pick's disease is unknown. In this study, we examined the prevalence of MAPT p.A152T in the largest series of neuropathologically confirmed Pick's disease cases to date (

Indexed as

MAPT p.A152TPick’s diseaserare varianttauopathy

Identifiers

PMID42553595
PMCPMC13435620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.